Re: Zenith Announces Initiation of Phase 1b ZEN-3694 Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Announces Initiation of Phase 1b ZEN-3694 Trial

in response to

Zenith Announces Initiation of Phase 1b ZEN-3694 Trial

BearDownAZ

posted on Dec 14, 2016 11:40AM

Re-posting a couple of my relevant posts from last week now that the offical news release is out.

Post 1: Looks like patients are now being invited to dance in ZEN-3694/Enzalutamide Combo Therapy trial. First site, UCSF, now recruiting. Nice timing, with the AGM/Corporate update coming in about a week. Could be interesting......

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Post 2: It is quite possible that the single agent ZEN-3694 dose escalation portion is complete and they have now found the maximally tolerated dose for ZEN-3694. Based on previous trial timelines from other presentations, this likely triggered 1) the start of the ZEN-3694/enzalutamide combo trial dose escalation and 2) expansion of the single agent ZEN-3694 to a larger population of patients at the optimal dose. Based on the start of recruiting for the combo trial, we know that #1 is happening. We may not hear about #2 until the AGM/Corporate Update. As San Fran wrote, it sure would be nice to hear about how those prostate tumors responded during the dose escalation.